share_log

ITeos Announces 2024 Strategic Priorities and Anticipated Milestones; Cash Balance And Investment Balance Of $644.9M As Of September 30, 2023 Expected To Provide Runway Through 2026

Benzinga ·  Jan 8 08:45
  • - TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC
  • - Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant's Phase 2 A2A-005 and EOS-984's Phase 1 trial
  • - EOS-984 preclinical data demonstrating novel mechanism of action in the adenosine pathway anticipated in second quarter of 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment